CA3234638A1 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors - Google Patents
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors Download PDFInfo
- Publication number
- CA3234638A1 CA3234638A1 CA3234638A CA3234638A CA3234638A1 CA 3234638 A1 CA3234638 A1 CA 3234638A1 CA 3234638 A CA3234638 A CA 3234638A CA 3234638 A CA3234638 A CA 3234638A CA 3234638 A1 CA3234638 A1 CA 3234638A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- nitrogen
- sulfur
- oxygen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277343P | 2021-11-09 | 2021-11-09 | |
| US63/277,343 | 2021-11-09 | ||
| US202263354403P | 2022-06-22 | 2022-06-22 | |
| US63/354,403 | 2022-06-22 | ||
| PCT/US2022/049220 WO2023086319A1 (en) | 2021-11-09 | 2022-11-08 | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234638A1 true CA3234638A1 (en) | 2023-05-19 |
Family
ID=84541585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234638A Pending CA3234638A1 (en) | 2021-11-09 | 2022-11-08 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11970494B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4430042B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7782035B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022388555A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234638A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4430042T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067443T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4430042T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20260640T1 (cg-RX-API-DMAC7.html) |
| LT (1) | LT4430042T (cg-RX-API-DMAC7.html) |
| PL (1) | PL4430042T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT4430042T (cg-RX-API-DMAC7.html) |
| RS (1) | RS68112B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI4430042T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202600180T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023086319A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| TW202444717A (zh) * | 2023-05-03 | 2024-11-16 | 美商雅捷可斯治療公司 | Jak2抑制劑之形式及組合物 |
Family Cites Families (271)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2729545B2 (ja) | 1991-06-05 | 1998-03-18 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法 |
| DK152291D0 (da) | 1991-08-28 | 1991-08-28 | Danisco | Fremgangsmaade og kemiske forbindelser |
| US5994629A (en) | 1991-08-28 | 1999-11-30 | Novartis Ag | Positive selection |
| US5616537A (en) | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| FR2719843B1 (fr) | 1994-05-10 | 1996-06-07 | Synthelabo | Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique. |
| DE4441676A1 (de) | 1994-11-23 | 1996-05-30 | Basf Ag | Iminooxymethylenanilide, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19507913C2 (de) | 1995-03-07 | 1998-04-16 | Agfa Gevaert Ag | Farbfotografisches Silberhalogenidmaterial |
| BR9610592A (pt) | 1995-09-18 | 1999-07-06 | Basf Ag | Composto processo para preparar o composto composição útil e processo para controlar pragas e uso do composto |
| CN1056370C (zh) | 1995-10-17 | 2000-09-13 | 化学工业部沈阳化工研究院 | 具有除草活性的4-芳氧(硫或氨)基嘧啶衍生物及其制备 |
| US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
| WO1999026932A1 (en) | 1997-11-26 | 1999-06-03 | Axys Pharmaceuticals, Inc. | By amidino group substituted heterocyclic derivatives and their use as anticoagulants |
| JPH11283746A (ja) | 1998-03-27 | 1999-10-15 | Fuji Photo Film Co Ltd | ビスベンゾアゾール化合物を用いたエレクトロルミネッセンス素子およびビスベンゾアゾール化合物の製造方法 |
| JP2002516328A (ja) | 1998-05-22 | 2002-06-04 | スミスクライン・ビーチャム・コーポレイション | G−csf模倣物 |
| AU752272B2 (en) | 1998-05-22 | 2002-09-12 | Smithkline Beecham Corporation | G-CSF mimetics |
| US6329383B1 (en) | 1999-01-25 | 2001-12-11 | Pharmacia Ab | 2-amino-5-pyrimidine acetic acid compounds |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| MXPA01010231A (es) | 1999-04-12 | 2003-07-21 | Aventis Pharma Ltd | Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina. |
| JP4000711B2 (ja) | 1999-04-13 | 2007-10-31 | 東レ株式会社 | 発光素子 |
| ATE281433T1 (de) | 1999-05-05 | 2004-11-15 | Aventis Pharma Ltd | Substituierte pyrrolidine als inhibitoren der zelladhäsion |
| EP1065208A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| ATE345349T1 (de) | 1999-12-17 | 2006-12-15 | Ariad Pharma Inc | Purinderivate |
| US7115589B2 (en) | 1999-12-17 | 2006-10-03 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
| AU2277201A (en) | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Novel purines |
| US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| GB0004686D0 (en) | 2000-02-28 | 2000-04-19 | Aventis Pharma Ltd | Chemical compounds |
| AU2001238690A1 (en) | 2000-03-14 | 2001-09-24 | Sepracor, Inc. | 3-substituted piperidines comprising urea functionality, and methods of use thereof |
| US6548517B2 (en) | 2000-03-24 | 2003-04-15 | Millennium Pharmaceuticals, Inc. | Oxindole inhibitors of factor Xa |
| US6469026B2 (en) | 2000-03-24 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Isoquinolone inhibitors of factor Xa |
| US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| US20030009034A1 (en) | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
| US20030109714A1 (en) | 2001-03-22 | 2003-06-12 | Neil Wishart | Transition metal mediated process |
| US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| WO2003045929A1 (en) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| US20040006117A1 (en) | 2002-02-15 | 2004-01-08 | Schering Aktiengesellschaft | Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| EP2319838A1 (en) | 2002-06-07 | 2011-05-11 | Cortical Pty Ltd | Therapeutic Molecules and Methods-1 |
| JP2005535631A (ja) | 2002-06-27 | 2005-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | プリン誘導体の合成 |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| WO2004006849A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
| JP2004067629A (ja) | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| EP1553075B1 (en) | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| AU2003284142A1 (en) | 2002-10-15 | 2004-05-04 | Synta Pharmaceuticals Corp | Aromatic bicyclic heterocyles to modulate 1L-12 production |
| AU2003302657B8 (en) | 2002-12-04 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Fused 1,3-dihydroimidazole ring compounds |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| KR101049348B1 (ko) | 2003-05-05 | 2011-07-13 | 톰슨 라이센싱 | 상이한 멀티플 콘텐츠 등급들을 갖는 텔레비전 신호를차단하는 시스템 및 방법 |
| WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| EP1682126B1 (en) | 2003-10-16 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Substituted benzazoles and use thereof as inhibitors of raf kinase |
| US7256196B1 (en) | 2003-12-09 | 2007-08-14 | The Procter & Gamble Company | Purine cytokine inhibitors |
| US7301036B2 (en) | 2003-12-19 | 2007-11-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| JP4528013B2 (ja) | 2004-04-01 | 2010-08-18 | 三井化学株式会社 | アントラセン化合物、および該アントラセン化合物を含有する有機電界発光素子 |
| TWI380816B (zh) | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-12(il-12)生成之二鹽抑制劑 |
| WO2005112932A2 (en) | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7371264B2 (en) | 2004-08-26 | 2008-05-13 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| US7371737B2 (en) | 2004-09-09 | 2008-05-13 | Solvay Pharmaceuticals, B.V. | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity |
| AR050630A1 (es) | 2004-09-09 | 2006-11-08 | Solvay Pharm Bv | DERIVADOS DE 6- TRIFLUOROMETIL PURINA 2- SUSTITUIDA CON ACTIVIDAD ANTAGONISTA DE ADENOSINA-A3. PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS. |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| MX2007004783A (es) | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
| WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| US20090118200A1 (en) | 2005-05-23 | 2009-05-07 | Bergman Jeffrey M | Proline bis-amide orexin receptor antagonists |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| WO2006130469A1 (en) | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| KR20080028424A (ko) | 2005-07-11 | 2008-03-31 | 이데미쓰 고산 가부시키가이샤 | 질소 함유 헤테로환 유도체 및 그것을 사용한 유기전기발광 소자 |
| KR20080028425A (ko) | 2005-07-11 | 2008-03-31 | 이데미쓰 고산 가부시키가이샤 | 전자흡인성 치환기를 갖는 질소 함유 헤테로환 유도체 및그것을 사용한 유기 전기발광 소자 |
| JP2007039406A (ja) | 2005-08-05 | 2007-02-15 | Idemitsu Kosan Co Ltd | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| DK2495016T3 (da) | 2005-12-23 | 2019-12-16 | Ariad Pharma Inc | Bicykliske heteroarylforbindelser |
| EP1976835A2 (en) | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2007091950A1 (en) | 2006-02-07 | 2007-08-16 | Astrazeneca Ab | Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2010530A2 (en) | 2006-03-23 | 2009-01-07 | Novartis AG | Methods for the preparation of imidazole-containing compounds |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| WO2008016666A2 (en) | 2006-08-02 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| NZ575410A (en) | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008070599A1 (en) | 2006-12-05 | 2008-06-12 | Chung-Ming Sun | Indazole compounds |
| RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
| US20080161254A1 (en) | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| WO2008124145A1 (en) | 2007-04-05 | 2008-10-16 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Steroid compounds, compositions, and methods of treatment |
| US8022085B2 (en) | 2007-05-07 | 2011-09-20 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| EP2170888B1 (en) | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CA2692761C (en) | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| EP2184285B1 (en) | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
| US20100261679A1 (en) | 2007-10-18 | 2010-10-14 | James Sutton | CSF-1R, Inhibitors, Compositions, and Methods of Use |
| JP2009149589A (ja) | 2007-12-24 | 2009-07-09 | Dnp Fine Chemicals Co Ltd | 非対称モノアザメチンシアニンの製造方法 |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| WO2010002492A1 (en) | 2008-04-29 | 2010-01-07 | University Of Chicago | Methods of use of adenine derivatives for the treatment of diabetes and other disorders |
| WO2009134850A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20100197688A1 (en) | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US20100093747A1 (en) | 2008-10-10 | 2010-04-15 | Erica Brook Goodhew | Method of inducing negative chemotaxis |
| EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| WO2010084300A2 (en) | 2009-01-22 | 2010-07-29 | Iti Scotland Limited | Stem cell culture methods |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010124097A2 (en) | 2009-04-22 | 2010-10-28 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| US20120172351A1 (en) | 2009-06-09 | 2012-07-05 | Nobuyuki Negoro | Novel fused cyclic compound and use thereof |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| JP5995728B2 (ja) | 2010-03-04 | 2016-09-21 | メルク・シャープ・エンド・ドーム・コーポレイション | カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 |
| EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| CN103601683B (zh) | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| US8815592B2 (en) | 2010-04-21 | 2014-08-26 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
| JPWO2011142381A1 (ja) | 2010-05-11 | 2013-08-29 | 藤田 岳 | ベンゾ若しくはピリドイミダゾール誘導体 |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物 |
| AU2011271462A1 (en) | 2010-06-30 | 2013-01-10 | Amgen Inc. | Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| WO2012020742A1 (ja) | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| KR101889993B1 (ko) | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US8710082B2 (en) | 2011-02-18 | 2014-04-29 | Board Of Trustees Of Michigan State University | Benzimidazole inhibition of biofilm formation |
| CN103501610A (zh) | 2011-03-09 | 2014-01-08 | 西建阿维拉米斯研究公司 | Pi3激酶抑制剂和其用途 |
| WO2012178208A2 (en) | 2011-06-24 | 2012-12-27 | The Trustees Of The Stevens Institute Of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| MX2014000452A (es) | 2011-07-15 | 2014-03-21 | Shionogi & Co | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). |
| US9445596B2 (en) | 2011-08-08 | 2016-09-20 | California Institute Of Technology | Small molecule compounds for the control of nematodes |
| US9487551B2 (en) | 2011-08-08 | 2016-11-08 | California Institute Of Technology | Small molecule compounds that control mammal-pathogenic nematodes |
| KR20140052032A (ko) | 2011-08-17 | 2014-05-02 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| US20130090327A1 (en) | 2011-09-30 | 2013-04-11 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| US10292390B2 (en) | 2011-11-04 | 2019-05-21 | Wisconsin Alumni Research Foundation | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
| JP6124351B2 (ja) | 2012-02-09 | 2017-05-10 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| US9284299B2 (en) | 2012-02-10 | 2016-03-15 | University Of Utah Research Foundation | Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions |
| CN104321322A (zh) | 2012-03-30 | 2015-01-28 | 理森制药股份公司 | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 |
| WO2013166545A2 (en) | 2012-05-07 | 2013-11-14 | The University Of Queensland | 6-oxopurine phosphoribosyltransferase inhibitors |
| AU2013204604B2 (en) | 2012-05-30 | 2016-05-19 | Biodiem Limited | Method of treating Scedosporium spp. infection |
| CA2874303C (en) | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| US9040498B2 (en) | 2012-07-06 | 2015-05-26 | Research Foundation Of The City University Of New York | 1,2,3-Triazolyl purine derivatives |
| WO2014014874A1 (en) | 2012-07-17 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Pyrazole derivatives which inhibit leukotriene production |
| WO2014037340A1 (de) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| WO2014069426A1 (ja) | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
| GB201220157D0 (en) | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| WO2014175330A1 (ja) | 2013-04-24 | 2014-10-30 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-オキシベンズイミダゾールおよび5-オキシアザベンズイミダゾール誘導体 |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| JP2016169161A (ja) | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2809535T3 (es) | 2013-12-09 | 2021-03-04 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores de la actividad de TNF |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US10403825B2 (en) | 2014-02-27 | 2019-09-03 | Universal Display Corporation | Organic electroluminescent materials and devices |
| US9190620B2 (en) | 2014-03-01 | 2015-11-17 | Universal Display Corporation | Organic electroluminescent materials and devices |
| WO2015188369A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| US11279714B2 (en) | 2014-06-20 | 2022-03-22 | Institut Pasteur Korea | Anti-infective compounds |
| EP4037000B1 (de) | 2014-07-21 | 2025-04-16 | Merck Patent GmbH | Materialen für elektronische vorrichtungen |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
| US10059689B2 (en) | 2014-10-14 | 2018-08-28 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| JP2016079168A (ja) | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
| CN107108521A (zh) | 2014-10-28 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的杂环衍生物 |
| CA2968884A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| JP2016132649A (ja) | 2015-01-21 | 2016-07-25 | 大日本住友製薬株式会社 | 新規イミダゾピリジン誘導体およびその医薬用途 |
| WO2016119700A1 (en) | 2015-01-28 | 2016-08-04 | Jn Therapeutics | Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof |
| WO2016134091A1 (en) | 2015-02-19 | 2016-08-25 | St. Jude Children's Research Hospital, Inc. | Method for improving learning |
| WO2016161952A1 (zh) | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
| WO2016196991A1 (en) | 2015-06-04 | 2016-12-08 | Children's Hospital Medical Center | Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition |
| US10875833B2 (en) | 2015-06-12 | 2020-12-29 | Transitions Optical, Inc. | Alignment compounds |
| GB2545499A (en) | 2015-12-18 | 2017-06-21 | Cambridge Display Tech Ltd | Dopant, charge transfer salt and organic electronic device |
| WO2017053537A1 (en) | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| GB201603311D0 (en) | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| US20190135834A1 (en) | 2016-04-26 | 2019-05-09 | Shionogi & Co., Ltd. | 5-substituted azabenzimidazole derivative having ???? activation action |
| EP3459949A4 (en) | 2016-05-20 | 2020-04-08 | Shionogi & Co., Ltd | 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT |
| CN109843858B (zh) | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| AU2017336074A1 (en) | 2016-09-30 | 2019-03-28 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
| WO2018064498A1 (en) | 2016-09-30 | 2018-04-05 | Pairnomix, Llc | Methods of treating epilepsy and related neurological conditions |
| JP6899993B2 (ja) | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | 複素環化合物 |
| EP3539963A4 (en) | 2016-11-11 | 2020-05-13 | Hepo Pharmaceutical Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE |
| MA47233A (fr) | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| US20200268753A1 (en) | 2017-01-30 | 2020-08-27 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| CN110312528B (zh) | 2017-02-20 | 2022-02-18 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
| FR3064268A1 (fr) | 2017-03-23 | 2018-09-28 | Universite De Montpellier | Acyclonucleosides phosphonates, leurs prodrogues, et leur utilisation en tant que medicaments. |
| AU2018243749A1 (en) | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| CN108689942B (zh) | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| US10934255B2 (en) | 2017-04-26 | 2021-03-02 | The Board Of Trustees Of The University Of Illinois | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same |
| US11957931B2 (en) | 2017-04-26 | 2024-04-16 | Yale University | Compositions and methods for treating vitiligo |
| CN110582496A (zh) | 2017-05-03 | 2019-12-17 | 格勒诺布尔-阿尔卑斯大学 | 用于合成多样取代的嘌呤的方法 |
| WO2018204765A1 (en) | 2017-05-05 | 2018-11-08 | Pairnomix, Llc | Methods of treating epilepsy and kcnq2 related conditions |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| CN107383014B (zh) | 2017-06-21 | 2019-04-30 | 南方医科大学 | 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用 |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| EP3661496A4 (en) | 2017-08-01 | 2021-04-21 | Opal Biosciences Limited | TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS WITH SUBSTITUTED NITROSTYRENE COMPOUNDS |
| WO2019038683A1 (en) | 2017-08-24 | 2019-02-28 | Institute For Stem Cell Biology And Regenerative Medicine | COMPOUNDS TARGETING BRCA1 BRCT TANDEM DOMAINS, COMPOSITIONS AND RELATED METHODS |
| MX386699B (es) | 2017-10-11 | 2025-03-19 | Chemocentryx Inc | Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2 |
| JP7425724B2 (ja) | 2017-10-17 | 2024-01-31 | エピザイム,インコーポレイティド | Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体 |
| US20210213014A1 (en) | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| AU2018353150B2 (en) | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| JP2021035910A (ja) | 2017-11-01 | 2021-03-04 | 大日本住友製薬株式会社 | 置換プリン化合物 |
| KR102706420B1 (ko) | 2017-11-30 | 2024-09-13 | 솔브레인 주식회사 | 화합물 및 이를 포함하는 유기 발광 소자 |
| CN110092798A (zh) | 2018-01-29 | 2019-08-06 | 上海新契博生物科技有限公司 | 一种作为fgfr抑制剂的杂环化合物及其合成方法和应用 |
| WO2019217838A1 (en) | 2018-05-11 | 2019-11-14 | The University Of Arizona | Methods for treating or limiting development of cardiovascular disease-related neurological disorders |
| EP3820500A4 (en) | 2018-07-13 | 2022-04-13 | Teqla Therapeutics, Inc. | USE OF BCL6 INHIBITORS TO TREAT AUTOIMMUNE DISEASES |
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| CN117186092A (zh) | 2018-11-07 | 2023-12-08 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| JP2022511030A (ja) | 2018-12-05 | 2022-01-28 | アルデイラ セラピューティクス, インコーポレイテッド | 注射可能な製剤 |
| IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| WO2020176597A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| BR112021020055A2 (pt) | 2019-04-12 | 2021-12-07 | Mitobridge Inc | Indutores de hmox1 |
| AU2020271855B2 (en) | 2019-04-12 | 2025-11-27 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
| WO2020243457A1 (en) | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
-
2022
- 2022-11-08 CA CA3234638A patent/CA3234638A1/en active Pending
- 2022-11-08 SI SI202230273T patent/SI4430042T1/sl unknown
- 2022-11-08 FI FIEP22826728.2T patent/FI4430042T3/fi active
- 2022-11-08 DK DK22826728.2T patent/DK4430042T3/da active
- 2022-11-08 RS RS20260547A patent/RS68112B1/sr unknown
- 2022-11-08 JP JP2024526576A patent/JP7782035B2/ja active Active
- 2022-11-08 SM SM20260180T patent/SMT202600180T1/it unknown
- 2022-11-08 ES ES22826728T patent/ES3067443T3/es active Active
- 2022-11-08 PT PT228267282T patent/PT4430042T/pt unknown
- 2022-11-08 PL PL22826728.2T patent/PL4430042T3/pl unknown
- 2022-11-08 HR HRP20260640TT patent/HRP20260640T1/hr unknown
- 2022-11-08 US US17/982,663 patent/US11970494B2/en active Active
- 2022-11-08 AU AU2022388555A patent/AU2022388555A1/en active Pending
- 2022-11-08 EP EP22826728.2A patent/EP4430042B1/en active Active
- 2022-11-08 WO PCT/US2022/049220 patent/WO2023086319A1/en not_active Ceased
- 2022-11-08 LT LTEPPCT/US2022/049220T patent/LT4430042T/lt unknown
-
2024
- 2024-03-26 US US18/617,294 patent/US20240254125A1/en active Pending
-
2025
- 2025-09-16 JP JP2025153429A patent/JP2025178324A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240254125A1 (en) | 2024-08-01 |
| FI4430042T3 (fi) | 2026-05-15 |
| JP7782035B2 (ja) | 2025-12-08 |
| LT4430042T (lt) | 2026-06-25 |
| PT4430042T (pt) | 2026-05-06 |
| EP4430042A1 (en) | 2024-09-18 |
| HRP20260640T1 (hr) | 2026-06-19 |
| SMT202600180T1 (it) | 2026-07-16 |
| SI4430042T1 (sl) | 2026-07-31 |
| JP2025178324A (ja) | 2025-12-05 |
| WO2023086319A1 (en) | 2023-05-19 |
| US20230167110A1 (en) | 2023-06-01 |
| RS68112B1 (sr) | 2026-06-30 |
| ES3067443T3 (en) | 2026-05-22 |
| EP4430042B1 (en) | 2026-02-18 |
| US11970494B2 (en) | 2024-04-30 |
| AU2022388555A1 (en) | 2024-05-02 |
| TW202334139A (zh) | 2023-09-01 |
| DK4430042T3 (da) | 2026-04-13 |
| JP2024540292A (ja) | 2024-10-31 |
| PL4430042T3 (pl) | 2026-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7793540B2 (ja) | Jak2阻害薬としての6-ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール | |
| EP2318408B1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| EP3027616B1 (en) | Azaindole compounds as modulators of rorc | |
| AU2022268977A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| EP4430042B1 (en) | 6-hetero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors | |
| HK1219950A1 (en) | Pyrrolopyridine as a kinase inhibitor | |
| WO2022143856A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| AU2019353144B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
| JP7763767B2 (ja) | ヘテロアリール複素環式化合物およびその使用 | |
| AU2018340505B2 (en) | Novel heterocyclic compounds as modulators of mGluR7 | |
| JP2023518609A (ja) | 新規アミノピリミジン系egfr阻害剤 | |
| AU2023323738A1 (en) | Heterocyclic amide and urea compounds as jak2 inhibitors | |
| KR20150056550A (ko) | 키나제 억제제로서의 디히드로피롤리디노-피리미딘 | |
| AU2020403681A1 (en) | Compound and composition as pdgf receptor kinase inhibitor | |
| WO2023009708A1 (en) | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors | |
| WO2023009712A1 (en) | Heteroaryloxy thiazolo azines as jak2 inhibitors | |
| WO2024148247A2 (en) | Azaindazoles as jak2 inhibitors | |
| WO2023009709A1 (en) | Pyrazolo piperazines as jak2 inhibitors | |
| CN118201928A (zh) | 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250422 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250617 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250617 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250618 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20260304 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260331 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260730 |